- Home
- NSIT vs HRMY Comparison
NSIT vs HRMY Comparison
Compare NSIT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSIT | HRMY |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSIT | HRMY |
|---|---|---|
| Price | $110.62 | $35.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $116.25 | $44.11 |
| AVG Volume (30 Days) | 484.6K | ★ 658.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | ★ 0.97 | 0.55 |
| Revenue | ★ $8,247,180,000.00 | $868,453,000.00 |
| Revenue This Year | $3.79 | $19.75 |
| Revenue Next Year | $2.16 | $12.88 |
| P/E Ratio | $113.20 | ★ $62.00 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $63.62 | $25.52 |
| 52 Week High | $148.36 | $40.87 |
Technical Indicators
Market Signals| Indicator | NSIT | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 65.55 | 69.42 |
| Support Level | $105.78 | $35.05 |
| Resistance Level | $111.54 | $38.91 |
| Average True Range (ATR) | 6.09 | 1.04 |
| MACD | -0.21 | 0.36 |
| Stochastic Oscillator | 62.80 | 87.44 |
Price Performance
Historical ComparisonAbout NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.